amb-chminaca amb-chminaca amb-chminaca or mmb-chminaca (also known as ma-chminaca) is an indazole-based synthetic cannabinoid that is a potent agonist of the cb1 receptor and has been sold online as a designer drug. amb-chminacalegal statuslegal status ca: schedule ii de: npsg (industrial and scientific use only) uk: class b identifiers iupac name methyl (2s)-2--3-methylbutanoate cas number1863066-03-8(racemate)pubchem cid119026010chemspider32055578uniiou56jjp891y21a13wady(racemate)chemical and physical dataformulac21h29n3o3molar mass371.481 g·mol−13d model (jsmol)interactive image smiles coc((c(c)c)nc(c1=nn(c2=c1c=cc=c2)cc3ccccc3)=o)=o inchi inchi=1s/c21h29n3o3/c1-14(2)18(21(26)27-3)22-20(25)19-16-11-7-8-12-17(16)24(23-19)13-15-9-5-4-6-10-15/h7-8,11-12,14-15,18h,4-6,9-10,13h2,1-3h3,(h,22,25)/t18-/m0/s1key:crggxdstbhqlkj-sfhvurjksa-n legal status amb-chminaca is listed in the fifth schedule of the misuse of drugs act (mda) and therefore illegal in singapore as of may 2015. sweden's public health agency classified amb-chminaca as a narcotic substance, on january 18, 2019.